347 related articles for article (PubMed ID: 25478017)
1. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.
Kontsekova E; Zilka N; Kovacech B; Novak P; Novak M
Alzheimers Res Ther; 2014; 6(4):44. PubMed ID: 25478017
[TBL] [Abstract][Full Text] [Related]
2. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.
Kontsekova E; Zilka N; Kovacech B; Skrabana R; Novak M
Alzheimers Res Ther; 2014; 6(4):45. PubMed ID: 25478018
[TBL] [Abstract][Full Text] [Related]
3. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M
Lancet Neurol; 2017 Feb; 16(2):123-134. PubMed ID: 27955995
[TBL] [Abstract][Full Text] [Related]
5. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.
Novak P; Zilka N; Zilkova M; Kovacech B; Skrabana R; Ondrus M; Fialova L; Kontsekova E; Otto M; Novak M
J Prev Alzheimers Dis; 2019; 6(1):63-69. PubMed ID: 30569088
[TBL] [Abstract][Full Text] [Related]
6. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.
Joly-Amado A; Davtyan H; Serraneau K; Jules P; Zitnyar A; Pressman E; Zagorski K; Antonyan T; Hovakimyan A; Paek HJ; Gordon MN; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A; Morgan D
Neurobiol Dis; 2020 Feb; 134():104636. PubMed ID: 31629891
[TBL] [Abstract][Full Text] [Related]
7. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.
Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
9. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice.
Hovakimyan A; Antonyan T; Shabestari SK; Svystun O; Chailyan G; Coburn MA; Carlen-Jones W; Petrushina I; Chadarevian JP; Zagorski K; Petrovsky N; Cribbs DH; Agadjanyan MG; Ghochikyan A; Davtyan H
Sci Rep; 2019 Oct; 9(1):15455. PubMed ID: 31664089
[TBL] [Abstract][Full Text] [Related]
10. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease.
Novak P; Kovacech B; Katina S; Schmidt R; Scheltens P; Kontsekova E; Ropele S; Fialova L; Kramberger M; Paulenka-Ivanovova N; Smisek M; Hanes J; Stevens E; Kovac A; Sutovsky S; Parrak V; Koson P; Prcina M; Galba J; Cente M; Hromadka T; Filipcik P; Piestansky J; Samcova M; Prenn-Gologranc C; Sivak R; Froelich L; Fresser M; Rakusa M; Harrison J; Hort J; Otto M; Tosun D; Ondrus M; Winblad B; Novak M; Zilka N
Nat Aging; 2021 Jun; 1(6):521-534. PubMed ID: 37117834
[TBL] [Abstract][Full Text] [Related]
11. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.
Rosenmann H
Curr Alzheimer Res; 2013 Mar; 10(3):217-28. PubMed ID: 23534533
[TBL] [Abstract][Full Text] [Related]
13. First transgenic rat model developing progressive cortical neurofibrillary tangles.
Filipcik P; Zilka N; Bugos O; Kucerak J; Koson P; Novak P; Novak M
Neurobiol Aging; 2012 Jul; 33(7):1448-56. PubMed ID: 21196063
[TBL] [Abstract][Full Text] [Related]
14. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
15. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
16. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
17. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.
Umeda T; Eguchi H; Kunori Y; Matsumoto Y; Taniguchi T; Mori H; Tomiyama T
Ann Clin Transl Neurol; 2015 Mar; 2(3):241-55. PubMed ID: 25815351
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in tau-directed immunotherapy against Alzheimer's disease: an overview of pre-clinical and clinical development.
Ng PY; Chang IS; Koh RY; Chye SM
Metab Brain Dis; 2020 Oct; 35(7):1049-1066. PubMed ID: 32632666
[TBL] [Abstract][Full Text] [Related]
19. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
[TBL] [Abstract][Full Text] [Related]
20. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
Zilka N; Korenova M; Novak M
Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
